Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

Is Most-Watched Stock Target Corporation (TGT) Worth Betting on Now?

View original at finance.yahoo.com
Is Most-Watched Stock Target Corporation (TGT) Worth Betting on Now? Target (TGT) has been one of the most searched-for stocks on Zacks.com lately…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Zacks Consensus Estimate for Target's current quarter has changed -0.4% over the last 30 days

    60% confidence
  • The next fiscal year consensus EPS estimate for Target has changed +3.8% over the past month

    60% confidence
  • The current fiscal year consensus EPS estimate for Target has changed +4.1% over the last 30 days

    60% confidence
  • The consensus earnings estimate of $8.80 for Target's next fiscal year indicates a change of +6.3% from what Target is expected to report a year ago

    60% confidence
  • Target is expected to post earnings of $2.21 per share for the current quarter, indicating a change of +7.8% from the year-ago quarter

    60% confidence
  • Target shares returned -2.8% over the past month versus the Zacks S&P 500 composite's +4.8% change, while the Zacks Retail - Discount Stores industry gained 0.6%

    60% confidence
  • The consensus earnings estimate of $8.28 for Target's current fiscal year points to a change of +9.4% from the prior year

    60% confidence
  • Empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements

    60% confidence
  • Target receives a Zacks Rank #3 (Hold), driven by the size of recent consensus estimate change and three other earnings-estimate-related factors

    60% confidence

Data points we hold from this source

Target Corporation · eps+7.8 percent_yoy
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com